Patología inflamatoria y autoinmune de la vía biliar

  1. Senra, N. Vallejo
  2. Domínguez-Muñoz, J.E.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2020

Serie: 13

Número: 9

Páxinas: 497-502

Tipo: Artigo

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2020.05.021 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Resumen La patología inflamatoria de la vía biliar hace referencia a un grupo de enfermedades de tipo inflamatorio que afecta a la vía biliar intra y/o extrahepática. La patogenia de estas enfermedades es variable, dependiendo del tipo de enfermedad y estructuras afectas. Los orígenes pueden ser desde una litiasis enclavada hasta una reacción inflamatoria autoinmune. Las manifestaciones clínicas también variarán según la naturaleza de la enfermedad, siendo lo más habitual que se presente dolor en hipocondrio derecho e ictericia, aunque pueden abarcar desde un paciente asintomático con hallazgos analíticos a un paciente con fallo hepático. Los pilares diagnósticos de este tipo de enfermedades son la clínica, las pruebas analíticas y las técnicas de imagen. En ocasiones será necesario también la histología mediante biopsia hepática u otras técnicas. El tratamiento puede variar según el tipo de enfermedad y los síntomas del paciente, abarcando desde el manejo sintomático y el drenaje endoscópico de la vía biliar hasta la cirugía. Inflammatory bile duct disease refers to a group of inflammatory diseases that affect the intrahepatic and extrahepatic bile duct. The pathogenesis of these diseases varies depending on the type of disease and affected structures. The origins can range from an embedded lithiasis to an autoimmune inflammatory reaction. The clinical manifestations also vary according to the nature of the disease, and the most common are pain in the right hypochondrium and jaundice, although the presentation can extend from no symptoms with suggestive laboratory findings to hepatic failure. The diagnostic bases for this type of disease are its symptoms, laboratory tests and imaging techniques. Occasionally, histology through liver biopsy or other techniques might be necessary. The treatment can vary depending on the type of disease and symptoms, encompassing the management of symptoms, endoscopic drainage of the bile duct and surgery.

Referencias bibliográficas

  • European Association for the Study of the Liver. EASL Clinical practice guidelines: the diagnosis and management of patients with primary biliary colangitis. J Hepatol. 2017;67:145-72.
  • Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagno-sis of primary biliary cirrhosis? Clin Gastroenterol Hepatol. 2003;1:89-95.
  • Taal BG, Schalm SW, de Bruyn AM, de Bruyn AM, de Rooy FW, Klein F. Serum IgM in primary biliary cirrhosis. Clin Chim Acta. 1980;108:457-63.
  • Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:701-12.
  • Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK – PBC primary biliary colangitis treatment and management guidelines. Gut. 2018;67:1588-94.
  • Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology. 2012;143:1492-501.
  • Nevens F, Andreone P, Mazzella G, Strasser SI1, Bowlus C1, In-vernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-43.
  • Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Hori-guchi N, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in pa-tients with primary biliary cirrhosis and dyslipidemia. Am J Gastroente-rol. 2015;110:423-31.
  • Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis. 1991;11:11-17.
  • Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, et al. British Society of Gastroentero-logy and UK – PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356-78.
  • Lindor KD, Kowdley KV, Harrison ME, American College of Gastroen-terology. ACG Clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646-59.
  • Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malin-choc M, et al. A revised natural history model for primary sclerosing cho-langitis. Mayo Clin Proc. 2000;75:688-94.
  • Angulo P, Pearce DH, Johnson CD, Henry JJ, LaRusso NF, Petersen BT, et al. Magnetic resonance cholangiography in patients with biliary disea-se: its role in primary sclerosing cholangitis. J Hepatol. 2000;33:520-7.
  • Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102:1528-36.
  • Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In pri-mary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97:1138-42.
  • Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:901-10.
  • Allison MC, Sandoe JA, Tighe R, Simpson IA, Hall RJ, Elliott TS; En-doscopy Committee of the British Society of Gastroenterology. Antibio-tic prophylaxis in gastrointestinal endoscopy. Gut. 2009;58:869-80.
  • Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21-30.
  • Tanaka A, Tazuma S, Okazaki K, Nakazawa T, Inui K, Chiba T, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017; 15(6):920-926.e3.
  • Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis. 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536-42.
  • Huggett MT, Culver EL, Kumar M, Hurst JM, Rodríguez-Justo M, Cha-pman MH, et al. Type 1 autoimmune pancreatitis and IgG4-related scle-rosing cholangitis is associated with extrapancreatic organ failure, malig-nancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109(10):1675-83.
  • Tanaka A. Inmunoglobulin G4-related esclerosing colangitis. J Dig Dis. 2019;20:357-62.
Fonte de datos: Dialnet